Johnson & Johnson (JNJ) News Today

Johnson & Johnson (NYSE:JNJ) saw its stock price increase today, driven by upbeat analyst forecasts, promising drug developments, strong earnings guidance, and insider confidence.

• Positive Sentiment: Johnson & Johnson was one of four major stocks to raise its 2025 guidance after solid Q2 results, prompting Wall Street upgrades and upward target revisions. 4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise (JNJ)
• Positive Sentiment: Analyst firm Leerink Partnrs raised its FY2028 EPS forecast for J&J to $13.63 from $12.77, reflecting stronger long-term earnings potential. FY2028 Earnings Forecast for JNJ Issued By Leerink Partnrs
• Positive Sentiment: JNJ filed for FDA approval of its oral psoriasis drug icotrokinra after Phase III trials showed strong skin clearance and a favorable safety profile. JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
• Positive Sentiment: Johnson & Johnson submitted a New Drug Application to the FDA for icotrokinra, aiming to shift the plaque psoriasis treatment paradigm with a once-daily oral medication. Johnson & Johnson Seeks First Icotrokinra U.S. FDA Approval
• Positive Sentiment: J&J’s pasritamig demonstrated breakthrough promise in prostate cancer, reinforcing its oncology pipeline strength. Johnson & Johnson (JNJ)’s Pasritamig Shows Breakthrough Promise in Prostate Cancer
• Positive Sentiment: Investors highlighted J&J as a top dividend stock and overlooked dividend leader, drawn by its reliable payout and yield. Build Stability and Income With 3 Overlooked Dividend Leaders (JNJ) Johnson & Johnson (JNJ) Is a Top Dividend Stock Right Now: Should You Buy?
• Positive Sentiment: U.S. Rep. Gilbert Ray Cisneros, Jr. purchased $15K–$50K of J&J shares, signaling insider confidence. Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Johnson & Johnson (NYSE:JNJ)
• Positive Sentiment: Analysts spotlighted J&J among oncology leaders set to benefit from surging demand for next-generation cancer therapies. Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
• Positive Sentiment: A strong Q2 earnings beat and full-year guidance raise fueled recommendations to add J&J to portfolios. Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
• Positive Sentiment: Jim Cramer noted 15 separate positive surprises at J&J, underscoring strong business momentum. Johnson & Johnson (JNJ): I Counted 15 Separate Surprises,” Says Jim Cramer
• Neutral Sentiment: An article suggested J&J stock “could be waking up,” highlighting valuation appeal but offering no new catalyst. Johnson & Johnson Stock Could Be Waking Up
• Neutral Sentiment: Zacks.com noted heightened attention on J&J as a trending stock, but refrained from a clear buy/sell verdict. Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
• Negative Sentiment: CNBC reported J&J among stocks with significant insider sales over the past week, which can be viewed as a cautious signal. Insider report: These stocks had the biggest sales by executives in the past week